Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Triton on acquisition of Fläkt Woods
Mandate

Vinge advises Triton on acquisition of Fläkt Woods

August 24, 2016 M&A

Vinge advises funds managed by Triton in connection with the acquisition of Fläkt Woods Group. Fläkt Woods Group is a global leader for air technologies on air treatment, air diffusion and air movement. Closing of the transaction is subject to applicable regulatory approvals. The company, with locations in 25 countries in all regions of the world, earns EUR 423 million in sales. It employs more than 2,100 people.

The Vinge team includes Christina Kokko together with Matthias Pannier and Johanna Wiberg (corporate), Johan Cederblad (environmental), Andréa Nicolin (commercial contracts), Anna Lonergan (real estate), Tomas Forsgren (IP), Linn Gustavsson (compliance), Karin Isacson (employment) och Mika Jordan (IT).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024